Synlogic (NASDAQ:SYBX) – Equities researchers at Wedbush raised their Q2 2018 EPS estimates for Synlogic in a research note issued to investors on Tuesday, May 15th. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.49) per share for the quarter, up from their previous estimate of ($0.79). Wedbush also issued estimates for Synlogic’s Q3 2018 earnings at ($0.52) EPS, Q4 2018 earnings at ($0.54) EPS, FY2018 earnings at ($2.10) EPS, FY2019 earnings at ($2.11) EPS, FY2020 earnings at ($1.96) EPS, FY2021 earnings at ($1.90) EPS and FY2022 earnings at ($0.81) EPS.
A number of other research firms also recently commented on SYBX. HC Wainwright set a $20.00 price objective on shares of Synlogic and gave the stock a “buy” rating in a report on Friday, May 11th. ValuEngine raised shares of Synlogic from a “strong sell” rating to a “sell” rating in a report on Friday, April 27th. Zacks Investment Research downgraded shares of Synlogic from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Piper Jaffray reissued a “buy” rating and set a $15.00 price objective on shares of Synlogic in a report on Monday, April 9th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Synlogic has an average rating of “Hold” and a consensus price target of $20.00.
Synlogic (NASDAQ:SYBX) last released its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.18. The company had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.21 million.
Several hedge funds and other institutional investors have recently made changes to their positions in the business. NEA Management Company LLC lifted its holdings in shares of Synlogic by 10.7% in the first quarter. NEA Management Company LLC now owns 4,229,410 shares of the biotechnology company’s stock valued at $39,672,000 after purchasing an additional 410,000 shares in the last quarter. Farallon Capital Management LLC purchased a new stake in shares of Synlogic in the first quarter valued at about $9,146,000. Sofinnova Ventures Inc purchased a new stake in shares of Synlogic in the first quarter valued at about $5,393,000. Artal Group S.A. purchased a new stake in shares of Synlogic in the fourth quarter valued at about $5,335,000. Finally, Texas Treasury Safekeeping Trust Co. purchased a new stake in shares of Synlogic in the first quarter valued at about $975,000. 56.20% of the stock is currently owned by institutional investors.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.